Roche Acquiring Cervical Cancer Test Developer MTM Laboratories for up to $269M | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Roche today announced an agreement to acquire MTM Laboratories for up to €190 million ($269 million) in a deal that expands Roche's capabilities in cervical cancer testing.

Roche will pay an upfront fee of €130 million and up to €60 million in milestone payments. Upon completion of the acquisition, MTM will become part of Roche's Tissue Diagnostics business unit. Roche said it expects to close the deal in the coming weeks.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.